Patent ID: 7517653

Claim:
A method for diagnosis, in male patients of the adenocarcinoma of the prostate or benign prostatic hyperplasia, comprising: determining from a serum sample the concentration of at least one tissue-specific marker and the concentration of at least one marker for inflammation, wherein said tissue-specific marker is PSA, and said marker for inflammation is ACT; determining a ratio based on the combination of the concentration of at least said tissue-specific marker and at least said inflammation marker, said ratio being as follows: [ACT]×[Total PSA] 2 /[Free PSA]; and making a diagnosis of adenocarcinoma of the prostate when the ratio is greater than 30 (μg/ml) 2 or making a diagnosis of benign prostatic hyperplasia when the ratio is below 16.5 μg/ml) 2 .